Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos

At Lietuvos sveikatos mokslu universiteto ligonine Kauno klinikos, investigators are evaluating innovative treatments for a broad spectrum of cancers and blood disorders, with the goal of extending survival and preserving quality of life.

• Advanced melanoma and non‑small cell lung cancer
• Acute myeloid leukemia and myelodysplastic syndromes
• Prostate and bladder cancer
• Gastric and esophageal cancers
• Head and neck squamous cell carcinoma
• Renal cell carcinoma
• Myelofibrosis and other hematologic malignancies

These trials focus on testing targeted agents, immunotherapies, and combination regimens to assess safety and effectiveness.

Researchers conduct clinical trials on heart disease, hypertension, and metabolic conditions, aiming to lower cardiovascular risk and protect kidney function.

• Atherosclerotic cardiovascular disease and heart failure
• Chronic kidney disease with proteinuria
• Type 2 diabetes inadequately controlled
• LDL‑C and triglyceride‑lowering therapies
• Thromboembolic prevention after orthopedic surgery
• Cardiovascular outcomes with novel lipid‑lowering agents

The studies evaluate whether new medications can reduce heart attacks, strokes, or progression of renal impairment.

The department explores immune‑mediated conditions, seeking durable remission while minimizing adverse effects.

• Crohn’s disease and ulcerative colitis
• Rheumatoid arthritis and psoriatic arthritis
• Hidradenitis suppurativa and atopic dermatitis
• Systemic sclerosis and lupus nephritis
• Relapsing‑multiple sclerosis
• Immune thrombocytopenia and chronic urticaria

Trials often compare novel biologics or small molecules with standard care to determine efficacy and safety.

Clinical research targets disorders of the nervous system, focusing on disease‑modifying strategies and symptom control.

• Relapsing‑multiple sclerosis and secondary progressive MS
• Migraine prevention
• Neurogenic detrusor overactivity
• Neuro‑imaging biomarkers in MS
• Neuro‑inflammation in multiple sclerosis
• Neuro‑vascular complications after stroke

These studies assess long‑term safety of disease‑modifying therapies and their impact on disability progression.

The site evaluates therapies for lung infections and chronic respiratory illnesses, aiming to reduce exacerbations and improve pulmonary function.

• Acute respiratory distress syndrome (ARDS)
• Chronic obstructive pulmonary disease (COPD)
• Community‑acquired pneumonia and COVID‑19
• Bronchiectasis
• Complicated urinary tract infections (as an infectious focus)
• Bacterial skin and soft‑tissue infections

Research includes antimicrobial agents and anti‑inflammatory drugs to shorten hospital stays and prevent complications.

Studies address both common and severe skin conditions, testing innovative biologics and small‑molecule inhibitors.

• Atopic dermatitis
• Chronic spontaneous urticaria
• Psoriasis and psoriatic arthritis
• Hidradenitis suppurativa
• Neovascular age‑related macular degeneration (ocular but related skin)
• Skin involvement in systemic diseases

The aim is to achieve rapid symptom relief and durable skin clearance with improved safety profiles.

Research includes growth disorders in children, evaluating hormone therapies to support normal development.

• Short stature due to Turner syndrome or small for gestational age
• Growth hormone deficiency
• Acquired antithrombin deficiency affecting surgery
• Hormonal regulation in metabolic disease
• Bone health in chronic kidney disease
• Endocrine aspects of rare genetic syndromes

Trials compare weekly versus daily growth hormone regimens to determine optimal height velocity and safety.